Proteinase 3-specific antineutrophil cytoplasmic antibody-associated vasculitis

Area of Science:

• Immunology
• Rheumatology
• Pathology

Background:

• Proteinase 3 (PR3)-specific antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a major variant linked to granulomatosis with polyangiitis (GPA).
• GPA is characterized by necrotizing granulomatous inflammation, primarily affecting the respiratory tract, and shares small vessel vasculitis features with microscopic polyangiitis.
• B cells play a central role in the pathogenesis of PR3-ANCA-associated vasculitis.

Purpose of the Study:

• To describe the histopathological and clinical features of PR3-ANCA-associated vasculitis.
• To elucidate the pathophysiology of PR3-ANCA-associated vasculitis.
• To review current and future targeted treatments for PR3-ANCA-associated vasculitis.

Main Methods:

• Literature review of histopathological and clinical features.
• Analysis of pathophysiological mechanisms involving neutrophils, monocytes, and B cells.
• Evaluation of current and emerging therapeutic strategies, including rituximab and novel immunotherapies.

Main Results:

• PR3-ANCA-associated vasculitis and GPA involve necrotizing granulomatous inflammation and small vessel vasculitis.
• B cell activation is crucial, with rituximab showing efficacy in remission induction and maintenance.
• Relapses and treatment toxicities remain significant challenges, highlighting the need for better therapies.

Conclusions:

• PR3-ANCA-associated vasculitis requires effective and less toxic treatments due to ongoing mortality and morbidity.
• Cellular and novel antigen-specific immunotherapies show promise for treating this autoimmune condition.
• Understanding the interplay of inflammation, immune cells, and targeted therapies is key to managing PR3-ANCA-associated vasculitis.